Raquel Afonso Caserta Eid

Raquel Afonso Caserta Eid

Auto-generated profile, based on publicly available information

Raquel Afonso Caserta Eid

Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2021 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
TCThiago Domingos Corrêa
Thiago Domingos Corrêa
TMThais Dias Midega
Thais Dias Midega
KTKarina Tavares Timenetsky
Karina Tavares Timenetsky
RCRicardo Luiz Cordioli
Ricardo Luiz Cordioli
CBCarmen Silvia Valente Barbas
Carmen Silvia Valente Barbas
LFLeonardo José Rolim Ferraz
Leonardo José Rolim Ferraz
Objective: To describe clinical characteristics, resource use, outcomes, and to identify predictors of in-hospital mortality of patients with COVID-19 admitted to the intensive care unit. Methods: Retrospective single-center cohort study conducted at a private hospital in São Paulo (SP), Brazil. All consecutive adult (≥18 years) patients admitted to the intensive care unit, between March 4, 2020 and February 28, 2021 were included in this study. Patients were categorized between survivors and non-survivors according to hospital discharge. Results: During the [...] ABSTRACT Objective: To describe clinical characteristics, resource use, outcomes, and to identify predictors of in-hospital mortality of patients with COVID-19 admitted to the intensive care unit. Methods: Retrospective single-center cohort study conducted at a private hospital in São Paulo (SP), Brazil. All consecutive adult (≥18 years) patients admitted to the intensive care unit, between March 4, 2020 and February 28, 2021 were included in this study. Patients were categorized between survivors and non-survivors according to hospital discharge. Results: During the

29 May 2020 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
TCThiago Domingos Corrêa
Thiago Domingos Corrêa
GMGustavo Faissol Janot de Matos
Gustavo Faissol Janot de Matos
BBBruno de Arruda Bravim
Bruno de Arruda Bravim
RCRicardo Luiz Cordioli
Ricardo Luiz Cordioli
AGAlejandra del Pilar Gallardo Garrido
Alejandra del Pilar Gallardo Garrido
LFLeonardo José Rolim Ferraz
Leonardo José Rolim Ferraz
In December 2019, a series of patients with severe pneumonia were identified in Wuhan, Hubei province, China, who progressed to severe acute respiratory syndrome and acute respiratory distress syndrome. Subsequently, COVID-19 was attributed to a new betacoronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Approximately 20% of patients diagnosed as COVID-19 develop severe forms of the disease, including acute hypoxemic respiratory failure, severe acute respiratory syndrome, acute respiratory distress syndrome and acute renal failure and require intensive care. There is no randomized controlled clinical trial addressing potential therapies for patients with confirmed COVID-19 infection at the time of publishing these treatment recommendations. Therefore, these recommendations are based predominantly on the opinion of experts (level C of recommendation).

31 July 2020 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
TCThiago Domingos Corrêa
Thiago Domingos Corrêa
GMGustavo Faissol Janot de Matos
Gustavo Faissol Janot de Matos
BBBruno de Arruda Bravim
Bruno de Arruda Bravim
RCRicardo Luiz Cordioli
Ricardo Luiz Cordioli
AGAlejandra del Pilar Gallardo Garrido
Alejandra del Pilar Gallardo Garrido
LFLeonardo José Rolim Ferraz
Leonardo José Rolim Ferraz
Dear Editor, In this issue of einstein journal (São Paulo), Corrêa et al., reported intensive support recommendations for critically-ill patients with suspected or confirmed infection by the new coronavirus (COVID-19).() Based on preliminary demonstration of efficacy of chloroquine, the authors suggested the use of hydroxychloroquine in monotherapy or combined with a macrolide (azithromycin or clarithromycin), to treat severe patients with COVID-19, admitted to the intensive care unit (ICU), to inhibit in vitro replication of severe acute respiratory syndrome coronavirus 2 [...] Dear Editor, In this issue of einstein journal (São Paulo), Corrêa et al., reported intensive support recommendations for critically-ill patients with suspected or confirmed infection by the new coronavirus (COVID-19).() Based on preliminary demonstration of efficacy of chloroquine, the authors suggested the use of hydroxychloroquine in monotherapy or combined with a macrolide (azithromycin or clarithromycin), to treat severe patients with COVID-19, admitted to the intensive care unit (ICU), to inhibit in vitro replication of severe acute respiratory syndrome coronavirus 2

5 July 2023 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
TCThiago Domingos Corrêa
Thiago Domingos Corrêa
TMThais Dias Midega
Thais Dias Midega
RCRicardo Luiz Cordioli
Ricardo Luiz Cordioli
CBCarmen Silvia Valente Barbas
Carmen Silvia Valente Barbas
RFRoberto Rabello Filho
Roberto Rabello Filho
LFLeonardo José Rolim Ferraz
Leonardo José Rolim Ferraz
Highlights We compared characteristics between patients admitted during the first and second waves. There were 1,427 intensive care unit patients with COVID-19: 421 (first wave) and 1,006 (second wave). The patients in the second wave were younger and less severely ill at the time of intensive care unit admission. Patients exhibited similar mortality rates and need for invasive organ support. ABSTRACT Objective To describe and compare the clinical characteristics and outcomes of patients admitted to intensive care units during the

28 July 2023 in Canadian Journal of Respiratory Therapy
Verified
Journal Article
Open access
PDF file
MNMilena Siciliano Nascimento
Milena Siciliano Nascimento
CTClaudia Talerman
Claudia Talerman
RERaquel A. C. Eid
Raquel A. C. Eid
SBSimone Brandi
Simone Brandi
LGLuana L.S. Gentil
Luana L.S. Gentil
FTFabiano B. Targa
Fabiano B. Targa
Objective: To evaluate the ability of the Perme Score to detect changes in the level of mobility of patients with COVID-19 outside the intensive care unit. Method: A retrospective cohort study was conducted in inpatient units of a private hospital. Patients older than 18, diagnosed with COVID-19, who were discharged from the intensive care unit and remained in the inpatient units were included. The variables collected included demographic characterization data, length of hospital stay, respiratory support, Perme Score values at admission to the inpatient unit and at hospital discharge and the mobilization phases performed during physical therapy. Result: A total of 69 patients were included, 80% male and with a mean age of 61.9 years (SD=12.5 years). The comparison of the Perme Score between the times of admission to the inpatient unit and at hospital discharge shows significant variation, with a mean increase of 7.3 points (95%CI:5.7-8.8; p <0.001), with estimated mean values of Perme Score at admission of 17.5 (15.8; 19.3) and hospital discharge of 24.8 (23.3; 26.3). There was no association between Perme Score values and length of hospital stay (measure of effect and 95%CI 0.929 (0.861; 1.002; p =0.058)). Conclusion: The Perme Score proved effective for assessing mobility in patients diagnosed with COVID-19 with prolonged hospitalization outside the intensive care setting. In addition, we demonstrated by the value of the Perme Score that the level of mobility increases significantly from the time of admission to inpatient units until hospital discharge. There was no association between the Perme Score value and length of hospital stay.

2 July 2025 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
GCGustavo Rodrigues das Chagas
Gustavo Rodrigues das Chagas
AVAléxia Gabriela da Silva Vieira
Aléxia Gabriela da Silva Vieira
JAJamile Caroline Garbuglio de Araújo
Jamile Caroline Garbuglio de Araújo
RERaquel Afonso Caserta Eid
Raquel Afonso Caserta Eid
CMCaroline Gomes Mól
Caroline Gomes Mól
RNRicardo Kenji Nawa
Ricardo Kenji Nawa
Objective To systematically review and analyze studies investigating the efficacy and safety of inspiratory muscle training in adult chronic critically ill patients. Methods The MEDLINE, Embase, CENTRAL, LILACS, Clinical Trials Registry, and World Health Organization databases were queried on November 24, 2022 and January 22, 2025. The review was conducted in accordance with the PRISMA guidelines. RevMan V5.4 was used to analyze mean differences or standardized mean differences and 95% confidence intervals (95%CIs) for continuous variables and risk ratios